Structure Therapeutics INC 10-Q quarterly reports

Structure Therapeutics Inc. filed its Form 10-Q for the period ended June 30, 2026, detailing increased R&D expenses and a substantial net loss, while highlighting progress in its clinical pipeline.

Structure Therapeutics Inc. reported increased R&D expenses and a wider net loss for Q1 2026, while maintaining a strong cash position.

Structure Therapeutics reports increased net losses in Q3 2025, driven by higher R&D, while advancing its obesity and IPF clinical programs and securing additional capital.

Structure Therapeutics reported significantly increased net losses in Q2 2025 driven by a substantial rise in research and development expenses as it advances its oral small molecule pipeline.

Structure Therapeutics reports a net loss of $46.8 million for Q1 2025, while advancing its clinical programs, including aleniglipron and LTSE-2578.

Structure Therapeutics reports positive topline data from its Phase 2a obesity study of GSBR-1290, showing a clinically meaningful and statistically significant placebo-adjusted mean decrease in weight of 6.2% at 12 weeks, and initiates a Phase 2b trial.

Structure Therapeutics announced positive topline results from its Phase 2a obesity study, showing a clinically meaningful 6.2% placebo-adjusted mean weight decrease at 12 weeks, and provided an update on its financial position and clinical programs.

Structure Therapeutics reports a net loss of $26 million for the first quarter of 2024, while highlighting progress in its clinical programs and a strong cash position.